Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656

Next Previous
Trial Profile

A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutivacaftor (Primary) ; Ivacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Concert Pharmaceuticals

Most Recent Events

  • 21 Sep 2016 According to a Concert Pharmaceuticals media release, results from this study will be presented at the 30th Annual North American Cystic Fibrosis Conference.
  • 10 Jun 2016 Results from this trial were presented at the European Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.
  • 10 Jun 2016 Results published in a Concert Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top